The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Sivolap Iu.P.

Moskovskaia meditsinskaia akademiia im. I.M. Sechenova

Anxiety associated with substance abuse

Authors:

Sivolap Iu.P.

More about the authors

Read: 5469 times


To cite this article:

Sivolap IuP. Anxiety associated with substance abuse. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(11‑2):3‑8. (In Russ.)
https://doi.org/10.17116/jnevro20161161123-8

Recommended articles:
Pathogenetic inte­rrelations of hypo­gonadism and depression in men. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):17-23
Clinical and psychopathological features of treatment-resistant schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):43-50
Depression Anxiety Stress Scale (russian language version). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):103-107
Conscious seda­tion with benzodiazepines in pediatric outpatient dentistry. Russian Journal of Anesthesiology and Reanimatology. 2025;(3):55-63
Dysfunctional pelvic pain in women. Russian Journal of Pain. 2025;(2):32-37

References:

  1. Latt N, Conigrave K, Saunders JB, Marshall EJ, Nutt D. Addiction Medicine. Oxford: Oxford University Press; 2009.
  2. Morissette A, Ouellet-Plamondon C, Jutras-Aswad D. Craving as a core symptom in substance use disorders: epidemiology, neurobiological substrates and clinical relevance. Sante Ment Que. 2014;39(2):21-37. doi:10.7202/1027830ar
  3. Trincavelli ML, Da Pozzo E, Daniele S, Martini C. The GABAA-BZR complex as target for the development of anxiolytic drugs. Curr Top Med Chem. 2012;12(4):254-269. doi:10.2174/1568026799078787
  4. Shackman AJ, Fox AS, Oler JA, Shelton SE, Oakes TR, Davidson RJ, Kalin NH. Heightened extended amygdala metabolism following threat characterizes the early phenotypic risk to develop anxiety-related psychopathology. Mol Psychiatry. 2016. doi:10.1038/mp.2016.132
  5. Black JJ, Clark DB, Martin CS, Kim KH, Blaze TJ, Creswell KG, Chung T. Course of alcohol symptoms and social anxiety disorder from adolescence to young adulthood. Alcohol Clin Exp Res. 2015;39(6):1008-1015. doi:10.1111/acer.12711
  6. Alegría AA, Hasin DS, Nunes EV, Liu SM, Davies C, Grant BF, Blanco C. Comorbidity of generalized anxiety disorder and substance use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2010;71(9):1187-1195. doi:10.4088/JCP.09m05328gry
  7. Hasin D, Kilcoyne B. Comorbidity of psychiatric and substance use disorders in the United States: current issues and findings from the NESARC. Curr Opin Psychiatry. 2012;25(3):165-171. doi:10.1097/YCO.0b013e3283523dcc
  8. Soyka M. Comorbidity of Anxiety Disorders and Substance Use. In: Dom G., Moggi F. (Editors). Co-occuring Addictive and Psychiatric Disorders: A Practice-Based Handbook from a European Perspective. Berlin: Springer; 2015;149-160. doi:10.1007/978-3-642-45375-5_19
  9. Avedisova AS. To the question of dependence to benzodiazepines. Psikhiatriya i psikhofarmakoterapiya. 1999;1:78-84. (In Russ.).
  10. Ganz DA, Bao Y, Shekelle PG, Rubenstein LZ. Will my patient fall? JAMA. 2007;297(1):77-86. doi:10.1001/jama.297.1.77
  11. Murphy Y, Wilson E, Goldner EM, Fischer B. Benzodiazepine use, misuse, and harm at the population level in Canada: a comprehensive narrative review of data and developments since 1995. Clin Drug Investig. 2016;36(7):519-530. doi:10.1007/s40261-016-0397-8
  12. Generoso MB, Trevizol AP, Kasper S, Cho HJ, Cordeiro Q, Shiozawa P. Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis. Int Clin Psychopharmacol. 2016. doi:10.1097/YIC.0000000000000147
  13. Montgomery SA, Lyndon G, Almas M, Whalen E, Prieto R. Early improvement with pregabalin predicts endpoint response in patients with generalized anxiety disorder: an integrated and predictive data analysis. Int Clin Psychopharmacol. 2016. doi:10.1097/YIC.0000000000000144
  14. Förg A, Hein J, Volkmar K, Winter M, Richter C, Heinz A, Müller CA. Efficacy and safety of pregabalin in the treatment of alcohol withdrawal syndrome: a randomized placebo-controlled trial. Alcohol Alcohol. 2012;47(2):149-155. doi:10.1093/alcalc/agr153
  15. Guglielmo R, Martinotti G, Clerici M, Janiri L. Pregabalin for alcohol dependence: a critical review of the literature. Adv Ther. 2012;29(11):947-957. doi:10.1007/s12325-012-0061-5
  16. Semple D, Smyth R. Oxford Handbook of Psychiatry (Third Edition). Oxford: Oxford University Press; 2013;1057. doi:10.1093/med/9780199693887.001.0001
  17. Soyka M, Grunze H. Pharmacotherapy of Dual Disorders. In: Dom G., Moggi F. (Editors). Co-occuring Addictive and Psychiatric Disorders: A Practice-Based Handbook from a European Perspective. Berlin: Springer; 2015;279-306. doi:10.1007/978-3-642-45375-5_19
  18. Schatzberg AF, DeBattista C. Manual of Clinical Psychopharmacology. Eighth Edition. Washington: American Psychiatric Publishing; 2015.
  19. Ibragimov DF. Alymemazine in medical practice. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2008;108(9):76-78. (In Russ.).
  20. Younus M, Labellarte MJ. Insomnia in children: when are hypnotics indicated? Paediatr Drugs. 2002;4(6):391-403. doi:10.2165/00128072-200204060-00006
  21. Bello LL. Factors affecting efficacy of oral trimeprazine sedation for dental procedures in children: A retrospective study. Saudi Dent J. 23(2):87-90. doi:10.1016/j.sdentj.2011.01.004
  22. Bailey MA, Saraswatula A, Dale G, Softley L. Paediatric sedation for imaging is safe and effective in a district general hospital. Br J Radiol. 2016;89(1061):20150483. doi:10.1259/bjr.20150483
  23. François M, Teissier N, Barthod G, Nasra Y. Sedation for children 2 to 5 years of age undergoing auditory brainstem response and auditory steady state responses recordings. Int J Audiol. 2012;51(4):282-286. doi:10.3109/14992027.2011.601469
  24. Mohammadi R, Gaudoneix-Taieb M, Armand-Branger S, Beauverie P, Poisson N. Value of trimeprazine among hypnotics in a psychiatric facility. Encephale. 2000;26(5):75-80.
  25. Yakhno NN, Parfenov VA, Reyhart DV, Belostotsky AV, Arnautov VS. The multicenter non-interventional, prospective observational program on the study of practical use of teraligen in patients diagnosed with autonomic disorder (START2): a local Russian experience with the use of the Russian version of The Four-Dimensional Symptom Questionnaire (4DSQ). An intermediate analysis. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2015;115(5):27-33. (In Russ.).
  26. Barancevich ER, Golovkova MS, Dzhulaj IA, Posohina OV, Starikov PV. The efficacy and safety of teraligen in patients with brain ischemia, stages I and II, and psychoautonomic syndrome. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2015;115(12):86-91. (In Russ.). doi:10.17116/jnevro201511511286-91
  27. Mendelevich VD. Craving: phenomenological analysis. Narkologiya. 2010;5:94-100. (In Russ.).
  28. Zobin ML. Problem drinking as an object of therapeutic intervention. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2013;113:6:2:14-19. (In Russ.).
  29. Kishi T, Sevy S, Chekuri R, Correll CU. Antipsychotics for primary alcohol dependence: a systematic review and meta-analysis of placebo-controlled trials. J Clin Psychiatry. 2013;74(7):642-654. doi:10.4088/JCP.12r08178
  30. Mann K. Pharmacotherapy of alcohol dependence: a review of the clinical data. CNS Drugs. 2004;18(8):485-504. doi:10.2165/00023210-200418080-00002

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.